Evidence map›Paper›PMID 39290040›Full record

ArticleThe Laryngoscope2025

Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis.

Mihai A Bentan, Graham Pingree, Lawrance Lee, Thomas Fitzpatrick, Theodore Schuman

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Laryngoscope, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Cannabis Use and Risk of Chronic Rhinosinusitis and Sinus Surgery.Laryngoscope investigative otolaryngology · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mihai A BentanDepartment of Otolaryngology - Head and Neck Surgery, Virginia Commonwealth University Health Systems, Richmond, Virginia, U.S.A.ORCID 0009-0001-4408-4176
Graham PingreeDepartment of Otolaryngology - Head and Neck Surgery, Virginia Commonwealth University Health Systems, Richmond, Virginia, U.S.A.
Lawrance LeeDepartment of Otolaryngology - Head and Neck Surgery, Virginia Commonwealth University Health Systems, Richmond, Virginia, U.S.A.ORCID 0000-0001-9408-3799
Thomas FitzpatrickDepartment of Otolaryngology - Head and Neck Surgery, Virginia Commonwealth University Health Systems, Richmond, Virginia, U.S.A.
Theodore SchumanDepartment of Otolaryngology - Head and Neck Surgery, Virginia Commonwealth University Health Systems, Richmond, Virginia, U.S.A.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare the efficacy of th2-targeted biologic medications (dupilumab, omalizumab, and mepolizumab) on absolute risk reduction (ARR) of functional endoscopic sinus surgery (FESS) in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP) and allergic fungal rhinosinusitis (AFRS).

methodsThe TriNetX Research Network database was queried for each mAb's market lifespan through March 2024. Adults with CRSwNP were propensity score matched against non-mAb controls based on age, sex, race, and asthma diagnosis. The primary outcome was rate of FESS, with secondary outcomes including inpatient admission, emergency department (ED) visit, and incidence of acute sinusitis. Subgroup analysis was performed for patients with AFRS.

resultsAll mAbs decreased FESS risk (dupilumab, ARR 11.48%, 95% CI 9.82%-13.15%, p < 0.001; omalizumab, ARR 12.02%, 95% CI 4.36%-19.68%, p = 0.002; mepolizumab, ARR 10.32%, 95% CI 5.24%-15.40%, p < 0.001) in CRSwNP patients. Only dupilumab also reduced risk of inpatient admission (ARR 8.59%, 95% CI 7.04%-10.15%, p < 0.001), ED visit (ARR 5.94%, 95% CI 4.28%-7.61%, p < 0.001), and acute sinusitis (ARR 2.60%, 95% CI 1.09%-4.12%, p = 0.001). In AFRS patients, only dupilumab reduced the risk of all outcomes: FESS (ARR 6.97%, 95 CI 2.86%-11.09%, p = 0.001), inpatient admission (ARR 16.93%, 95% CI 11.30%-22.57%, p < 0.001), ED visit (ARR 13.15%, 95% CI 7.15%-19.14%, p < 0.001), and acute sinusitis (ARR 7.17%, 95% CI 2.18%-12.17%, p = 0.005).

conclusionAlthough all mAbs reduced FESS risk in CRSwNP, only dupilumab reduced secondary outcomes as well. Similarly, only dupilumab improved all outcomes in AFRS patients. These data demonstrate the potential of mAbs in reducing disease burden and enhancing patient outcomes in CRSwNP and AFRS. LEVEL OF EVIDENCE: NA Laryngoscope, 135:593-601, 2025.

Indexed as

Biological ProductsMycosesNasal PolypsRhinitisRhinitis, AllergicSinusitisAdultAllergic Fungal SinusitisAntibodies, Monoclonal, HumanizedChronic DiseaseEndoscopyFemaleHumansMaleMiddle AgedOmalizumabAntibodies, Monoclonal, HumanizedBiological ProductsdupilumabmepolizumabOmalizumaballergic fungal sinusitischronic rhinosinusitisendoscopic sinus surgeryFESS

Identifiers

PMID39290040
PMCPMC11725712

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.